Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab for MRD Elimination and Remission Maintenance in Hematologic Malignancies Post-Allo-SCT
NCT02985554Phase 1Terminated
- Sponsor
- University of Chicago
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in hematologic malignancy, sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose at 24 months. Started Mar 2017; status: terminated.
02
Drugs
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02985554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985554.